The most prevalent genetic abnormalities identified in prostate cancer include point mutations in genes such as SPOP, FOXA1, and TP53, alongside copy number alterations (CNAs) affecting AR, MYC, RB1, PTEN, CHD1, and fusion genes associated with the ETS (E26 transformation-specific) family [26,30,31,32,33,34,35,36]. This evidence concerns the gene FOXA1 and prostate carcinoma.